In one of the larger biopharma IPOs in 2023, Cargo Therapeutics Inc. pulled in $281.3 million on Nov. 10, selling 18.75 million shares at $15 each, the low end of its price range. The market debut comes just eight months after the San Mateo, Calif.-based company raised $200 million in an oversubscribed series A round.
The artificial intelligence company Recursion Pharmaceuticals Inc. and Bayer AG have upped the ante on their 2020 collaboration deal to include precision oncology, with the possibility of more than $1 billion in potential milestone payments for Recursion.
MYC amplification and p53 mutations are common in several human cancers. DNA topoisomerase II-β-binding protein (TopBP1) functions at the intersection of Rb, PI3K/Akt and p53 pathways and thus could be a promising cancer therapeutic target.
A Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. patent describes new ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer
Work at Beijing Tide Pharmaceutical Co. Ltd. has led to the development of proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety coupled to an EGFR (HER1; erbB1)-targeting moiety through a linker.
Sichuan Haisco Pharmaceutical Co. Ltd. has developed pyrazinone derivatives acting as protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors. They are reported to be useful for the treatment of cancer.
Protein tyrosine kinase 7 (PTK7) is a pseudo tyrosine kinase overexpressed in many cancer types such as ovarian, triple-negative breast cancer (TNBC), non-small-cell lung cancer, small-cell lung cancer and bladder cancer, but limited expression in normal tissues.
Researchers from Biocytogen Pharmaceuticals (Beijing) Co. Ltd. and Doma Biopharmaceutical (Suzhou) Co. Ltd. reported the discovery and preclinical data of DM-005, a novel fully human EGFR × MET bispecific antibody-drug conjugate (ADC) being developed for the treatment of cancer.
A team of scientists at the University of Massachusetts Chan Medical School has discovered the putative cancer target UDP-glucuronate decarboxylase 1 (UXS1) in cancer cells expressing high levels of UDP-glucose 6-dehydrogenase (UGDH). UXS1 is a Golgi enzyme that appears downstream of UGDH and converts UDP-glucuronate (UDPGA) to UDP-xylose. The study also showed that UXS1 not only cleared away UDPGA but also limited its production through negative feedback on UGDH. They published their results on Oct. 25, 2023, in the online edition of Nature.
Nearly a year and a half after an interim analysis cast doubt on the future of Atara Biotherapeutics Inc.’s phase II study of ATA-188 in treating non-active progressive multiple sclerosis (PMS), the newly released primary analysis didn’t change much.
RSS
